

## BRAF35 Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-AP00964
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	20ul, 50ul, 100ul
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human HMG20B. AA range:1-50
<b>Mol wt</b>	35813
<b>Species reactivity</b>	Human
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	WB, IHC-p, IF, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	BRAF35 Antibody
<b>Synonyms</b>	HMG20B; BRAF35; HMGX2; HMGXB2; SMARCE1R; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related; SMARCE1-related protein; BRCA2-associated factor 35; HMG

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

### Recommended Dilution

WB: 1: 500 - 1: 2000


IHC: 1: 100 - 1: 300

IF: 1: 200 - 1: 1000


ELISA: 1: 20000

Not yet tested in other applications.


### Images



Western Blot analysis of AD293 cells using BRAF35 Polyclonal Antibody diluted at 1:2000 cells nucleus.



Western Blot analysis of various cells using BRAF35 Polyclonal Antibody diluted at 1:2000 cells nucleus.



Western blot analysis of lysates from Jurkat cells, using HMG20B Antibody. The lane on the right is blocked with the synthesized peptide.

### Storage

-20°C for one year

501 Changsheng S Rd, Nanhu Dist, Jiaxing, Zhejiang, China

Tel: 86 21 31007137 | E-mail: [save@bt-laboratory.com](mailto:save@bt-laboratory.com) | [www.bt-laboratory.com](http://www.bt-laboratory.com)